Vyriad Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vyriad Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11070
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vyriad Inc (Vyriad), formerly Omnis Pharma Inc is a clinical stage bio-pharmaceutical company that develops viral-based novel oncolytic therapies for the treatment of cancer. The company’s pipeline products include various engineered viruses in phase 1 for the treatment of non small cell lung cancer, bladder cancer, solid cancer, and Human Pappillomavirus (HPV). It also conducts investigator sponsored trials targeted against myeloma IV, ovarian cancer, endometrial cancer, multiple myeloma, T cell lymphoma, acute myeloid leukemia, metastatic breast cancer, medulloblastoma, and others. The company develops oncolytic virus therapies utilizing engineered viruses designed to destroy cancer. Vyriad is headquartered in Rochester, Minnesota, the US.

Vyriad Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vyriad Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vyriad Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vyriad Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vyriad Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Omnis Pharma Raises Funds in Seed Financing 11
Partnerships 12
Vyriad Enters into Licensing Agreement with Imanis Life Sciences 12
Vyriad Enters into Collaboration Agreement with Merck and Pfizer 13
Tessa Therapeutics and Vyriad Enter into Agreement 14
Profectus BioSciences Enters into Co-Development Agreement with Vyriad 15
Merger 16
Omnis Pharma and Magnis Therapeutics Merge 16
Licensing Agreements 17
Vyriad Enters into Licensing Agreement with StingInn 17
Omnis Pharma Enters into Licensing Agreement with Mayo Clinic Ventures 18
Vyriad Inc – Key Competitors 19
Vyriad Inc – Key Employees 20
Vyriad Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Strategy And Business Planning 22
May 10, 2018: Vyriad to Build State-of-the-Art Facility for Manufacturing Oncolytic Virus Anti-Cancer Vaccines in Rochester, Minn. 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Vyriad Inc, Pharmaceuticals & Healthcare, Key Facts 2
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vyriad Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vyriad Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vyriad Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vyriad Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Omnis Pharma Raises Funds in Seed Financing 11
Vyriad Enters into Licensing Agreement with Imanis Life Sciences 12
Vyriad Enters into Collaboration Agreement with Merck and Pfizer 13
Tessa Therapeutics and Vyriad Enter into Agreement 14
Profectus BioSciences Enters into Co-Development Agreement with Vyriad 15
Omnis Pharma and Magnis Therapeutics Merge 16
Vyriad Enters into Licensing Agreement with StingInn 17
Omnis Pharma Enters into Licensing Agreement with Mayo Clinic Ventures 18
Vyriad Inc, Key Competitors 19
Vyriad Inc, Key Employees 20

List of Figures
Vyriad Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vyriad Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vyriad Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vyriad Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Vyriad Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Armetheon Inc-製薬・医療分野:企業M&A・提携分析
    Summary Armetheon Inc (Armetheon) is a drug development company that develops novel small molecule drugs for treatment of cardiovascular diseases with high unmet medical need. The company develops anticoagulants and antibiotics that make use of the antibiotic resistance mechanisms to provide bacteri …
  • Acadia Pharmaceuticals Inc (ACAD)-製薬・医療分野:企業M&A・提携分析
    Summary Acadia Pharmaceuticals Inc (Acadia) discovers, develops and commercializes small molecule drugs for the treatment of central nervous system disorders. The company’s lead product Nuplazid (pimavanserin) is an FDA approved drug for the treatment of Parkinson’s disease psychosis. Acadia also de …
  • Piper Jaffray Companies:企業の戦略・SWOT・財務情報
    Piper Jaffray Companies - Strategy, SWOT and Corporate Finance Report Summary Piper Jaffray Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nanoco Group Plc (NANO):企業の財務・戦略的SWOT分析
    Nanoco Group Plc (NANO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Meyer Burger Technology AG (MBTN):企業の財務・戦略的SWOT分析
    Meyer Burger Technology AG (MBTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • DFDS AS (DFDS):企業の財務・戦略的SWOT分析
    DFDS AS (DFDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Grifols SA (GRF)-医療機器分野:企業M&A・提携分析
    Summary Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in …
  • Celulosa Arauco y Constitucion SA:企業の戦略的SWOT分析
    Celulosa Arauco y Constitucion SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Sonic Healthcare Limited:企業の戦略・SWOT・財務分析
    Sonic Healthcare Limited - Strategy, SWOT and Corporate Finance Report Summary Sonic Healthcare Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Hogan Lovells International LLP:企業の戦略的SWOT分析
    Hogan Lovells International LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • State Atomic Energy Corporation Rosatom-エネルギー分野:企業M&A・提携分析
    Summary State Atomic Energy Corporation Rosatom (ROSATOM), the Russian Federation national nuclear corporation, is a nuclear company that integrates nuclear companies and R&D institutions which operate in the civilian and defense sectors. It provides a variety of nuclear services that range from ura …
  • Bellerophon Therapeutics Inc (BLPH):企業の財務・戦略的SWOT分析
    Summary Bellerophon Therapeutics Inc (Bellerophon Therapeutics), formerly Bellerophon Therapeutics LLC is a clinical-stage biotherapeutics company that focuses on the development of therapies for the treatment of cardiopulmonary diseases. The company’s lead investigational cardiopulmonary product ca …
  • Malaysian Resources Corporation Berhad (MRCB):企業の財務・戦略的SWOT分析
    Malaysian Resources Corporation Berhad (MRCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Enel Russia (ENRU):電力:M&Aディール及び事業提携情報
    Summary Enel Russia, a subsidiary of Enel Investment Holding BV, is an energy utility. It produces electricity and thermal energy. The company generates electricity using coal, gas and fuel oil sources. Enel Russia owns and operates Konakovskaya GRES, Nevinnomysskaya GRES, Reftinskaya GRES and Sredn …
  • MonTa Biosciences ApS:製薬・医療:M&Aディール及び事業提携情報
    Summary MonTa Biosciences ApS (MonTa Biosciences) is a biotechnology company that develops and commercializes immuno-oncology therapeutics for cancer therapy. Its pipeline products include MBS2, and MBS5 used for the treatment of cancer and infectious diseases. The company’s technology is based on T …
  • Torrent Power Limited:企業の戦略・SWOT・財務情報
    Torrent Power Limited - Strategy, SWOT and Corporate Finance Report Summary Torrent Power Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Environics Oy:企業の戦略・SWOT・財務情報
    Environics Oy - Strategy, SWOT and Corporate Finance Report Summary Environics Oy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • IXICO Plc (IXI):企業の財務・戦略的SWOT分析
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints and assessing the safety and efficacy of drugs. The company offers products such as Assessa and trial tracker. Assessa provides web-based platform to tra …
  • Mizuho Financial Group Inc:企業の戦略・SWOT・財務情報
    Mizuho Financial Group Inc - Strategy, SWOT and Corporate Finance Report Summary Mizuho Financial Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Dohler GmbH:企業の戦略・SWOT・財務分析
    Dohler GmbH - Strategy, SWOT and Corporate Finance Report Summary Dohler GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆